BMRN News and Press, BioMarin Pharmaceutical Inc. From 12/21/23

2023-12-21 11:45:02 ET RBC Capital analyst issues SECTOR PERFORM recommendation for BMRN on December 21, 2023 12:00PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $94.52 at issue of the analyst recommendation. The overall analyst consen...

2023-12-21 11:11:55 ET More on BioMarin Pharmaceutical BioMarin: Keeping Bullish View After Q3 Earnings BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript BioMarin ...

2023-12-20 17:01:11 ET BioMarin ( NASDAQ: BMRN ) said that it has established a strategic review committee, temporarily expanded its board and entered into a cooperation agreement with key investor Elliott Investment Management. The biotech company said the new Strategic and Ope...

2023-12-15 12:11:32 ET More on BioMarin Pharmaceutical BioMarin: Keeping Bullish View After Q3 Earnings BioMarin Pharmaceutical 2023 Q3 - Results - Earnings Call Presentation Biomarin Pharmaceutical Q3 2023 Earnings Call Transcript BioMarin Pharmaceutical off...

2023-12-15 12:00:57 ET More on BioMarin Pharmaceutical BioMarin: Keeping Bullish View After Q3 Earnings BioMarin Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript Wells Far...

2023-12-12 20:24:54 ET Summary Ole Andreas Halvorsen's 13F stock portfolio value increased slightly to $24.64B, with 80 holdings. The largest positions in the portfolio are Visa, Workday, Amazon.com, United Parcel Service, and Danaher Corp. New stakes include Block Inc., Freep...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany PR Newswire ROCTAVIAN is First Gene Therapy for Hemophilia to Receive Approved Federal Price in Ger...

2023-11-25 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...